FSRT Combined With TMZ for Large BMs: a PSM Study

Status Completed

Clinical Trial Summary

A propensity- matched study was conducted to investigate the feasibility and safety of adding temozolomide to hypofractionated stereotactic radiotherapy for large brain metastases.

Clinical Trial Description

A previous single arm phase II trial of our institution has shown that HFSRT combined with concurrent TMZ was safe and efficient for patients with BMs of ≥ 6cc in volume. The 1-year local control and overall survival rate was better than the results of a retrospective study using HFSRT alone in treating BMs of ≥ 3cm in diameter. Thus, we hypothesized that adding TMZ to HFSRT should translate to substantive benefits in clinical outcomes compared to HFSRT alone. Propensity score matching method was adopted to decrease potential bias in this retrospective study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03338075
Study type	Observational
Source	Chinese Academy of Medical Sciences
Contact
Status	Completed
Phase	N/A
Start date	January 1, 2016
Completion date	August 1, 2017

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04074096` - Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis	Phase 2
Recruiting	`NCT04474925` - Pre- Versus Post-operative SRS for Resectable Brain Metastases	Phase 3
Recruiting	`NCT05358340` - Dual Perfusion Imaging for Characterizing Vascular Architecture of Brain Lesions	N/A
Recruiting	`NCT05559853` - Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
Completed	`NCT03189381` - Pilot Phase 2 Study Whole Brain Radiation Therapy With Simultaneous Integrated Boost for Patients With Brain Metastases	N/A
Completed	`NCT02082587` - Toronto BNB Pilot Study	N/A
Terminated	`NCT01551680` - A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases	Phase 1
Terminated	`NCT00717275` - Study of Temozolomide to Treat Newly Diagnosed Brain Metastases	Phase 2
Recruiting	`NCT05048212` - A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases	Phase 2
Recruiting	`NCT03714243` - Blood Brain Barrier Disruption (BBBD) Using MRgFUS in the Treatment of Her2-positive Breast Cancer Brain Metastases	N/A
Recruiting	`NCT05573815` - Evaluation of Clinical Decision Support System for Brain Metastasis Using Brain MR Images	N/A
Recruiting	`NCT04899908` - Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases	Phase 2
Completed	`NCT04507217` - Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC	Phase 2
Recruiting	`NCT05452005` - Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer	Phase 1
Recruiting	`NCT06457906` - SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC	Phase 3
Completed	`NCT04170777` - Perfexion Registration Using CBCT
Recruiting	`NCT03027544` - Tomotherapy for Refractory Brain Metastases	N/A
Completed	`NCT04178330` - Tomotherapy as Primary Radiotherapy for Multipule Brain Metastases	N/A
Terminated	`NCT02187822` - Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases	Phase 1
Terminated	`NCT00538343` - RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases	Phase 2